Boodhoo T - Search Results

Year	Number of Results
1998	1
2003	1
2009	1
2010	4
2018	1
2020	1
2021	1
2023	2
2024	1

1

Neutralizing Antibody Formation with OnabotulinumtoxinA (BOTOX^®) Treatment from Global Registration Studies across Multiple Indications: A Meta-Analysis.

Jankovic J, Carruthers J, Naumann M, Ogilvie P, Boodhoo T, Attar M, Gupta S, Singh R, Soliman J, Yushmanova I, Brin MF, Shen J. Jankovic J, et al. Among authors: boodhoo t. Toxins (Basel). 2023 May 17;15(5):342. doi: 10.3390/toxins15050342. Toxins (Basel). 2023. PMID: 37235376 Free PMC article.

2

OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial.

Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF; PREEMPT 2 Chronic Migraine Study Group. Diener HC, et al. Cephalalgia. 2010 Jul;30(7):804-14. doi: 10.1177/0333102410364677. Epub 2010 Mar 17. Cephalalgia. 2010. PMID: 20647171 Clinical Trial.

3

OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.

Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF; PREEMPT 1 Chronic Migraine Study Group. Aurora SK, et al. Cephalalgia. 2010 Jul;30(7):793-803. doi: 10.1177/0333102410364676. Epub 2010 Mar 17. Cephalalgia. 2010. PMID: 20647170 Clinical Trial.

4

Botulinum type A treatment: no evidence of increased risk of seizures in juvenile cerebral palsy.

Brin MF, Pogoda JM, Boodhoo T, Bowen B. Brin MF, et al. Among authors: boodhoo t. Clin Rehabil. 2010 Dec;24(12):1144-6; author reply 1446-7. doi: 10.1177/0269215510380834. Clin Rehabil. 2010. PMID: 21115685 Review. No abstract available.

5

Safety and tolerability of onabotulinumtoxinA in the treatment of upper facial lines from global registration studies in 5298 participants: A meta-analysis.

Brin MF, De Boulle K, Liew S, Carruthers A, Carruthers J, Rivkin A, Wu Y, Kawashima M, Yushmanova I, Boodhoo TI, Lee E. Brin MF, et al. Among authors: boodhoo ti. JAAD Int. 2023 Sep 9;14:4-18. doi: 10.1016/j.jdin.2023.07.021. eCollection 2024 Mar. JAAD Int. 2023. PMID: 38035126 Free PMC article.

6

Setipiprant for Androgenetic Alopecia in Males: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2a Trial.

DuBois J, Bruce S, Stewart D, Kempers S, Harutunian C, Boodhoo T, Weitzenfeld A, Chang-Lin JE. DuBois J, et al. Among authors: boodhoo t. Clin Cosmet Investig Dermatol. 2021 Oct 15;14:1507-1517. doi: 10.2147/CCID.S319676. eCollection 2021. Clin Cosmet Investig Dermatol. 2021. PMID: 34703265 Free PMC article. Clinical Trial.

7

Safety and Stability of Pulmonary Function in Patients with Decreased Respiratory Function Treated for Spasticity with OnabotulinumtoxinA.

Ayyoub Z, Brashear A, Banach M, Schoene R, Stringer W, Boodhoo T, Yushmanova I, Dimitrova R, Brin MF. Ayyoub Z, et al. Among authors: boodhoo t. Toxins (Basel). 2020 Oct 19;12(10):661. doi: 10.3390/toxins12100661. Toxins (Basel). 2020. PMID: 33086749 Free PMC article. Clinical Trial.

8

Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications.

Naumann M, Carruthers A, Carruthers J, Aurora SK, Zafonte R, Abu-Shakra S, Boodhoo T, Miller-Messana MA, Demos G, James L, Beddingfield F, VanDenburgh A, Chapman MA, Brin MF. Naumann M, et al. Among authors: boodhoo t. Mov Disord. 2010 Oct 15;25(13):2211-8. doi: 10.1002/mds.23254. Mov Disord. 2010. PMID: 20737546

9

Once-Daily Oral Sarecycline 1.5 mg/kg/day Is Effective for Moderate to Severe Acne Vulgaris: Results from Two Identically Designed, Phase 3, Randomized, Double-Blind Clinical Trials.

Moore A, Green LJ, Bruce S, Sadick N, Tschen E, Werschler P, Cook-Bolden FE, Dhawan SS, Forsha D, Gold MH, Guenthner S, Kempers SE, Kircik LH, Parish JL, Rendon MI, Rich P, Stein-Gold L, Tyring SK, Weiss RA, Nasir A, Schmitz C, Boodhoo TI, Kaoukhov A, Berk DR. Moore A, et al. Among authors: boodhoo ti. J Drugs Dermatol. 2018 Sep 1;17(9):987-996. J Drugs Dermatol. 2018. PMID: 30235387 Clinical Trial.

10

Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics.

Dahlén B, Nizankowska E, Szczeklik A, Zetterström O, Bochenek G, Kumlin M, Mastalerz L, Pinis G, Swanson LJ, Boodhoo TI, Wright S, Dubé LM, Dahlén SE. Dahlén B, et al. Among authors: boodhoo ti. Am J Respir Crit Care Med. 1998 Apr;157(4 Pt 1):1187-94. doi: 10.1164/ajrccm.157.4.9707089. Am J Respir Crit Care Med. 1998. PMID: 9563738 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

12 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year